Immune response in patients receiving a bioprosthetic heart valve: Lack of response with decellularized valves

Tissue Engineering - Part A

Volumn 17, Issue 19-20, 2011, Pages 2399-2405

  Bloch, Oliver ^a   Golde, Pia ^b   Dohmen, Pascal M ^c   Posner, Steffen ^a   Konertz, Wolfgang ^c   Erdbrügger, Wilhelm ^a  

^a AutoTissue Ltd   (Germany)

^b ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; BIOMINERALIZATION; COLLAGEN; IMMUNOLOGY; PATIENT TREATMENT;

ANTIBODY RESPONSE; ANTIBODY TITERS; BIOPROSTHETIC HEART VALVES; COLLAGEN I; COLLAGEN TYPE I; DECELLULARIZED; FOLLOW UP; GLUTARALDEHYDES; HEART VALVES; IMMUNE RESPONSE; IMMUNOGLOBULIN G; LIFE SPAN; SERUM SAMPLES;

ANTIBODIES;

BOVINAE; SUS;

ALPHA GALACTOSIDASE; COLLAGEN TYPE 1; GLUTARALDEHYDE;

ADULT; ANIMAL; ARTICLE; BIOPROSTHESIS; CATTLE; ENZYME ASSAY; FEMALE; HEART VALVE PROSTHESIS; HUMAN; IMMUNITY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SWINE;

ADULT; ALPHA-GALACTOSIDASE; ANIMALS; BIOPROSTHESIS; CATTLE; COLLAGEN TYPE I; ENZYME ASSAYS; FEMALE; GLUTARAL; HEART VALVE PROSTHESIS; HUMANS; IMMUNITY; MALE; MIDDLE AGED; SUS SCROFA;

EID: 80053111352     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2011.0046     Document Type: Review

References (39)

1. Casselman, F.P., Bots, M.L., Van Lommel, W., Knaepen, P.J., Lensen, R., and Vermeulen, F.E. Repeated thromboembolic and bleeding events after mechnaical aortic valve replacement. Ann Thorac Surg 71, 1172, 2001.
2. Maliwa, M.A., van derHeijden, G.J., Bots, M.L., van Hout, B.A., Casselman, F.P., van Swieten, H., and Vermeulen, F.E. Quality of life and NYHA class 30 years after mechanical aortic valve replacement. Cardiovasc Surg 11, 381, 2003.
3. Westaby, S. The stentless aortic bioprosthesis. In: Piwnica, A., Westaby, S., eds. Surgery for acquired aortic valve disease. Oxford: Isis Medical Media, 1997, pp. 83-101.
4. Carpentier, A., Lemaigre, G., Robert, L., Carpentier, S., and Duborst, C. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg 58, 467, 1969.
5. Levy, F.J. Glutaraldehyde and the calcification mechanism of bioprostetic heart valves. J Heart Valve Dis 3, 101, 1994.
6. Curcio, C.A., Commerford, P.J., Rose, A.G., Stevens, J.E., and Barnard, M.S. Calcification of glutaraldehyd-preserved porcine xenografts in young patients. J Thorac Cardiovasc Surg 81, 621, 1981.
7. Konakci, K.Z., Bohle, B., Blumer, R., Hoetzenecker, W., Roth, G., Moser, B., Boltz-Nitulescu, G., Gorlitzer, M., Klepetko, W., Wolner, E., and Ankersmit, H.J. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest 35, 17, 2005.
8. O'Brien, M.F., Harrocks, S., Stafford, E.G., Gardner, M.A., Pohlner, P.G., Tesar, P.J., and Stephens, F. Homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 10, 334, 2001.
9. Oei, F.B.S., Welters, M.J.P., Vaessen, L.M.B., Stegmann, A.P.A., Bogers, A.J.J.C., and Weimar, W. Induction of cytotoxic T lymphocytes with destructive potential after cardiac valve allograft implantation. J Heart Valve Dis 9, 761, 2000.
10. Steinhoff, G., Stock, U., Karim, N., Mertsching, H., Timke, A., Meliss, R.R., Pethig, K., Haverich, A., and Bader, A. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 102, 50, 2000.
11. Booth, C., Korossis, S.A., Wilcox, H.E., Watterson, K.G., Kearney, J.N., Fisher, J., and Ingham, E. Tissue engineering of cardiac valve prothesis I: development and histological characterization of an acellular porcine scaffold. J Heart Valve Dis 11, 457, 2002.
12. Kasimir, M.T., Rieder, E., Seebacher, G., Silberhumer, G., Wolner, E., Weigel, G., and Simon, P. Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs 26, 421, 2003.
13. Goldstein, S., Clarke, D.R., Walsh, S.P., Black, K.S., and O'Brien, M.F. Transpecies heart valve transplant: advanced studies of a bioengineered xeno-autograft. Ann Thorac Surg 70, 1962, 2000.
14. Simon, P., Kasimir, M.T., Rieder, P., Seebacher, G., Wolner, E., and Weigel, G. Presence and Elimination of the Xenoantigen Gal (a1, 3) Gal in Tissue-Engineered Heart Valves. Tissue Eng 11, 1274, 2005.
15. Sievers, H.H., Stierle, U., Schmidtke, C., and Bechtel, M. Decellularized pulmonary homograft (Synergraft) for reconstruction of the right ventricular outflow tract: first clinical experience. Z Kardiol 92, 53, 2003.
16. Erdbrü gger, W., Konertz, W., Dohmen, P.M., Posner, S., Ellerbrok, H., Brodde, O.E., Robenek, H., Modersohn, D., Pruss, A., Holinski, S., Stein-Konertz, M., and Pauli, G. Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng 12, 2059, 2006.
17. Dohmen, P.M., Ozaki, S., Verbeken, E., Yperman, J., Flameng, W., and Konertz, W. Tissue engineering of a pulmonary xenograft heart valve. Asian Cardiovasc Thoracic Surg 10, 25, 2002.
18. Dohmen, P.M., Ozaki, S., Yperman, J., Flameng, W., and Konertz, W. Lack of calcification of tissue engineered autoxenografts in juvenile sheep. Semin Thorac Cardiovasc Surg 13, 93, 2001.
19. Dohmen, P.M., da Costa, F., Yoshi, S., Lopes, S., da Souza, F., Vilani, R., Wouk, F., and Konertz, W. Results of a decellularized heart valve implanted into the juvenile sheep model. Heart Surg Forum 8, 100, 2005.
20. Costa, F.D.A., Dohmen, P., Lopes, S.V., Lacerda, G., Pohl, F., Vilani, R., Costa, M.B.A., Viera, E.D., Yoschi, S., Brofman, P., Konertz, W., and Costa, I.A. Comparison of cryopreserved homografts and decellularized porcine heterografts implanted in sheep. Artif Organs 28, 366, 2004.
21. Kasimir, M.T., Rieder, E., Seebacher, G., Nigisch, A., Dekan, B., Wolner, E., Weigel, G., and Simon, P. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 15, 278, 2006.
22. Simon, P., Kasimir, M.T., Seebacher, G., Weigel, G., Ullrich, R., Salzer-Muhar, U., Rieder, E., and Wolner, E. Early failure of the tissue engineered porcine heart valve SYNERGRAFTTM in pediatric patients. Eur J Cardiothorac Surg 23, 1002, 2003.
23. Enriquez-Verdugo, I., Guerriero, A.L., Serrano, J.J., Godinez, D., Rosales, J.L., Tenorio, V., and De La Garza, M. Adherence of Actinobacillus pleuropneumoniae to swine-lung collagen. Microbiology 150, 2391, 2004.
24. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248, 1976.
25. Murray, A., and Lawrence, G.P. How should the repeatability of clinical measurements be analysed? An assessment of analysis technique with data from cardiovascular autonomic function tests. Q J Med 12, 831, 1993.
26. Bastian, F., Stelzmü ller, M.E., Kratochwill, K., Kasimir, M.T., Simon, P., and Weigel, G. IgG deposition and activation of the classical complement pathway involvement in the activation of human granulocytes by decellularized porcine heart valve tissue. Biomaterials 29, 1824, 2008.
27. Schussler, O., Shen, M., Shen, L., Carpentier, S.M., Kaveri, S., and Carpentier, A. Effect of human immunoglobulins on the immunogenicity of porcine bioprostheses. Ann Thorac Surg 71, 396, 2001.
28. Schoen, L.J., and Levy, R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 79, 1072, 2005.
29. Lila, N., McGregor, C.G., Carpentier, S., Rancic, J., Byrne, G.W., and Carpentier, A. Gal knockout pig pericardium: new source of material for heart valve bioprostheses. J Heart Lung Transplant 29, 538, 2010.
30. Park, C.S., Park, S.S., Choi, S.Y., Yoon, S.H., Kim, W.H., and Kim, Y.J. Anti alpha-gal immune response following porcine bioprosthesis implantation in children. J Heart Valve Dis 19, 124, 2010.
31. Mangold, A., Szerafin, T., Hoetzenecker, K., Hacker, S., Lichtenauer, M., Niederpold, T., Nickl, S., Dworschak, M., Blumer, R., Auer, J., and Ankersmit, H.J. Alpha-Gal specific IgG immune response after implantation of bioprostheses. Thorac Cardiovasc Surg 57, 191, 2009.
32. Dohmen, P.M., Lembcke, A., Holinski, S., Kivelitz, D., Braun, J.P., Pruss, A., and Konertz, W. Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg 84, 729, 2007.
33. Bayrak, A., Tyralla, M., Ladhoff, J., Schleicher, M., Stock, U.A., Volk, H.D., and Seifert, M. Human immune responses to porcine xenogenic matrices and their extracellular matrix constituents in vitro. Biomaterials 31, 3793, 2010.
34. Jorge-Herrero, E., Fernandez, P., de la Torre, N., Escudero, C., Garcia-Paez, J.M., Bujan, J., and Castillo-Olivares, J.L. Inhibition of the calcification of porcine valve tissue by selective lipid removal. Biomaterials 15, 815, 1994.
35. Galili, U. The alpha-gal epithope (Gal alpha 1-3Gal beta 1-4GlccNAc-R) in xenotransplantation. Biochimie 83, 557, 2001.
36. Sandrin, M.S., and McKenzie, I.F.C. Gala(1,3) Gal, the major xenoantigen(s) recognized in pigs by human natural antibodies. Immunol Rev 141, 169, 1994.
37. Galili, U., Shohet, S.B., Korbin, E., Stults, C.L.M., and Macher, B.A. Man, apes and Old World monkeys differ from other mammals in the expression of a-galactosyl epitopes on nucleated cells. J Biol Chem 263, 17755, 1988.
38. Galili, U., Anaraki, F., Thal, A., Hill-Black, C., and Radic, M. One percent of human circulating B-lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82, 2485, 1993.
39. Human, P., and Zilla, P. Inflammatory and immune processes: the neglected villain of bioprosthethic degeneration? J Long Term Eff Med Implants 35, 199, 2001.